Leonor Vasconcelos de Matos

Dr. Leonor Vasconcelos de Matos

Centro Hospitalar Lisboa Ocidental
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
ACAugusto Caraceni
Augusto Caraceni
RSRaffaella Speranza
Raffaella Speranza
ESElio Spoldi
Elio Spoldi
CACristina Sonia Ambroset
Cristina Sonia Ambroset
SCStefano Canestrari
Stefano Canestrari
MDMassimo Damini
Massimo Damini

21 August 2023 in Journal of Science and Medicine in Sport
Verified
Journal Article
Open access
CMCarla Malveiro
Carla Malveiro
ICInês Correia
Inês Correia
CCCatarina Cargaleiro
Catarina Cargaleiro
JMJoão P. Magalhães
João P. Magalhães
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
MCMaria João Cardoso
Maria João Cardoso
This systematic review aimed to analyze the effects of different exercise protocols on physical fitness (cardiorespiratory fitness, muscle strength, and body composition), quality of life, cancer-related fatigue, and sleep quality in patients with different types of cancer undergoing neoadjuvant treatment. Systematic review. A comprehensive search of existing literature was carried out using four electronic databases: PubMed, Scopus, Web of Science, and Cochrane Library (published until October 19, 2022). All databases were searched for randomized controlled trials, quasi-experimental investigations, and pre-post investigations assessing the effects of exercise in cancer patients during neoadjuvant treatment. Excluded articles included multicomponent interventions, such as exercise plus diet or behavioral therapy, and investigations performed during adjuvant treatment or survivorship. The methodological quality of each study was assessed using the Physiotherapy Evidence Database (PEDro) scale. Twenty-seven trials involving 999 cancer patients were included in this review. The interventions were conducted in cancer patients undergoing neoadjuvant treatment for rectal (n = 11), breast (n = 5), pancreatic (n = 4), esophageal (n = 3), gastro-esophageal (n = 2), and prostate (n = 1) cancers, and leukemia (n = 1). Among the investigations included, 14 utilized combined exercise protocols, 11 utilized aerobic exercise, and two utilized both aerobic and resistance training separately. Exercise interventions appeared to improve cardiorespiratory fitness, muscle strength, body composition, and quality of life, although many investigations lacked a between-group analysis. Despite limited evidence, exercise interventions applied during neoadjuvant treatment demonstrate promising potential in enhancing cardiorespiratory fitness, muscle strength, body composition, and overall quality of life. However, a scarcity of evidence remains on the effects of exercise on cancer-related fatigue and sleep quality. Further research with high-quality randomized controlled trials is warranted.

17 February 2022 in Cureus
Verified
Journal Article
Open access
FAFátima R. Alves
Fátima R. Alves
LGLucia Gil
Lucia Gil
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
ABAna Baleiras
Ana Baleiras
AVAna Carolina Silva Henriques Vasques
Ana Carolina Silva Henriques Vasques
AMAna Martins
Ana Martins
In clinical practice, there is a binary distinction between human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative (HER2−) breast cancer (BC). However, within HER2− disease, there is significant heterogeneity. Particularly, HER2− tumors that express some level of HER2 by immunohistochemistry (IHC) score 1+ or 2+/in situ hybridization (ISH) non-amplified are currently defined as HER2-low. This subgroup has shown distinct biological features compared to HER2-zero (HER2-0) BC and additionally novel antibody-drug conjugate therapies have demonstrated a potential and promising activity in HER2-low BC population. This study aims to evaluate the impact of HER2-low status in response to neoadjuvant chemotherapy (NACT) in HER2− BC being HER2-low and HER2-0 status. In a single institution, we retrospectively reviewed clinical and pathological data of HER2 early-stage BC patients treated with NACT following definitive surgery from January 2015 to December 2020. Tumors with HER2 IHC 0 were classified as HER2-0 and IHC score 1+ and 2+/ISH non-amplified as HER2-low. The primary objective was to evaluate the rate of pathological complete response (pCR) using the definition of ypT0/Tis ypN0 according to HER2-low and HER2-0 subgroups. Secondary objectives were to evaluate biological features between the two subgroups, disease-free survival (DFS), and overall survival (OS). Pearson chi-square, Fisher’s exact, and Mann-Whitney tests were performed. The Kaplan-Meier method was used to plot DFS and OS curves. A p-value of <0.05 was considered statistically significant. A total of 72 patients with HER2 BC were included with a median age at diagnosis of 52.5 years and a median follow-up time of 35.5 months. Of patients, 56.9% had HER2-low disease and 43.1% had HER2-0 disease. Significant differences between the two subgroups were detected regarding hormonal receptor status and proliferation grade (Ki67). In the HER2-low subgroup, 70% of tumors were luminal-like and 64.5% of HER2-0 patients had triple-negative BC (p = 0.03). There were statistically significant differences regarding estrogen (p = 0.00) and progesterone (p = 0.02) receptors. The median Ki67 rate was higher in the HER2-0 subset (mean rank = 43.9) compared to HER2-low (mean rank = 30.9) and this difference was statistically significant (p = 0.00). HER2-low patients presented more stage III tumors (65.9%) and HER2-0 patients were mainly stage II (61.3%), and this was statistically relevant (p = 0.03). The prevalence of other clinical and pathological features was comparable between both groups. HER2-low subgroup achieved lower pCR rates (14.6% vs. 29.0%) but this difference was not statistically significant (p = 0.15). Similarly, there was no difference between the two subgroups regarding DFS (p = 0.97) and OS (p = 0.35), although the data were immature. As in prior studies, this study did not support a significant impact of HER2-low status on response to NACT in HER2− patients with early-stage BC. HER2-low patients had a lower pCR, which may suggest a worse response to classic chemotherapy regimen and may have clinical implications that should be further exploited. The prevalence of hormonal receptors in HER2-low tumors was consistent with previous data in the literature. Although retrospective, the data suggest that HER2-low tumors should be regarded as a distinct biological subtype and more research is warranted.

16 May 2024 in Cancer
Verified
Journal Article
Open access
Francesco SchettiniFrancesco Schettini
Francesco Schettini
EBEva Blondeaux
Eva Blondeaux
CMChiara Molinelli
Chiara Molinelli
RBRaphaëlle Bas
Raphaëlle Bas
HKHee Jeong Kim
Hee Jeong Kim
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged as a novel therapeutic target but has not been characterized in this rare patient subset.Methods: Women aged ≤40 years with newly diagnosed early‐stage HER2‐negative BC (HER2‐0 and HER2‐low) and germline BRCA1/2 PVs from 78 health care centers worldwide were retrospectively included. Chi‐square test and Student t‐test were used to describe variable distribution between HER2‐0 and HER2‐low. Associations with HER2‐low status were assessed with logistic regression. Kaplan–Meier method and Cox regression analysis were used to assess disease‐free survival (DFS) and overall survival. Statistical significance was considered for p ≤ .05.Results: Of 3547 included patients, 32.3% had HER2‐low BC, representing 46.3% of hormone receptor–positive and 21.3% of triple‐negative (TN) tumors. HER2‐low vs. HER2‐0 BC were more often of grade 1/2 (p < .001), hormone receptor–positive (p < .001), and node‐positive (p = .003). BRCA2 PVs were more often associated with HER2‐low than BRCA1 PVs (p < .001). HER2‐low versus HER2‐0 showed better DFS (hazard ratio [HR], 0.86; 95% CI, 0.76–0.97) in the overall population and more favorable DFS (HR, 0.78; 95% CI, 0.64–0.95) and overall survival (HR, 0.65; 95% CI, 0.46–0.93) in the TN subgroup. Luminal A–like tumors in HER2‐low (p = .014) and TN and luminal A‐like in HER2‐0 (p = .019) showed the worst DFS.Conclusions: In young patients with HER2‐negative BC and germline BRCA1/2 PVs, HER2‐low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal‐like disease. HER2‐low status was associated with a modestly improved prognosis.

1 January 2021 in Sage Open Medicine
Verified
Journal Article
Open access
PDF file
MNMaria Teresa Neves
Maria Teresa Neves
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
AVAna Carolina Vasques
Ana Carolina Vasques
ISInês Egídio Sousa
Inês Egídio Sousa
IFInês Ferreira
Inês Ferreira
KMKamal Mansinho
Kamal Mansinho
We aimed to compare clinical features of older age group and young and middle-aged patients with COVID-19 and analyze mortality predictors. Retrospective analysis of ongoing collection of prespecified data, on a single institution, including patients hospitalized consecutively due to COVID-19 infection, from March to June 2020. Of 195 patients, 56.9% were ⩾65 years (older age group). Older age group had multimorbidity (p < 0.001). At admission Early Warning Score-2 (p < 0.001), C-reactive protein, D-dimer, creatinine, anemia and lymphopenia were higher in older age group, as well as median time of hospitalization (14 vs 10 days, p = 0.004). Complications were more common in older age group, but there were no significant differences in admission to intensive care. There were 18 deaths, 16 in older age group. Modified Early Warning Score at admission (odds ratio = 1.60, 95% confidence interval = 1.07–1.37, p = 0.021) and C-reactive protein >5 mg/dL (odds ratio = 2.12, 95% confidence interval = 1.13–26.26, p = 0.034) were independent predictors of inhospital mortality in older age group but not in young and middle-aged. Older age group was at higher risk for complications and inhospital mortality. Identification of specific scores of severity for this population is essential to ensure that best care is provided.

20 October 2020 in CNS Oncology
Verified
Journal Article
Open access
LFLeonor Fernandes
Leonor Fernandes
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
DCDébora Cardoso
Débora Cardoso
MSMarlene Saraiva
Marlene Saraiva
RMRenata Medeiros-Mirra
Renata Medeiros-Mirra
AMAna Martins
Ana Martins
Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to ...